XV
Xvivo Perfusion AB (publ)
XVIPF · OTC
$30.95 +0.00% (+$0.00)
Market Cap 9.51B kr
P/E Ratio 107.72x
Div. Yield -
ROE 5.37%
Bulios Fair Price
$16.54
46.6% downside
Current Price
$30.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XVIPF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive P/E 107.72x
EV/EBITDA 51.78x
P/FCF 67.06x
Growth
83 /100
Growing EPS growth 8.87%
Rev. growth 24.95%
Book val. growth 13.81%
Profitability
76 /100
Strong Gross margin 66.41%
Net margin 9.91%
FCF margin 15.92%
Quality
77 /100
Excellent ROIC 30.36%
ROE 5.37%
Asset turnover 3.43x
Debt
100 /100
Low Debt/Equity 0.06x
Current ratio 3.86x
Net debt/EBITDA -0.10x
Stability
35 /100
Moderate Beta 1.46x
Rev. volatility 24.59%
Profitable years 5
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XVIPF
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Christoffer Rosenblad
Employees
210
Headquarters
Mölndal
Upcoming events
22 OCT
Earnings
Upcoming earnings report